| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2022: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2021: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2020: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we developed lipid nanoparticles (LNPs) loaded with two adjuvants to effectively induce memory natural killer (NK) cells, and demonstrated the cancer immunotherapy against PD-1 blockade (immune checkpoint inhibition therapy) resistant tumor. LNPs loaded with two types of adjuvants efficiently induce memory NK and enhance therapeutic efficacy against mouse melanoma lung metastasis that showed the resistant to PD-1 blockade. In addition, prophylactic administration can strongly suppress melanoma lung metastasis, suggesting that it may be effective in preventing metastasis of cancers that are resistant to immune checkpoint inhibition therapy.
|
